세계의 급성 신손상(AKI) 치료 시장 : 제품 유형별, 장애 유형별, 최종 사용자별 - 예측(2025-2030년)

The Acute Kidney Injury Treatment Market was valued at USD 1.87 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 7.81%, to USD 3.17 billion by 2030.

Acute Kidney Injury (AKI) treatment is an evolving segment in the healthcare market, rooted in the need for effective therapeutic interventions to manage sudden kidney function loss. The necessity of AKI treatment stems from its high morbidity and mortality rates, making early and accurate interventions crucial. Current applications focus on enhancing renal recovery, managing fluid balance, electrolyte disturbances, and minimizing further renal damage. These treatments serve hospitals, dialysis centers, and intensive care units, reflecting a high end-use scope across critical care settings. Key growth factors influencing this market include the rising prevalence of chronic diseases like diabetes and hypertension, an aging population, and advancements in diagnostic techniques and monitoring technologies. Potential opportunities lie in the development of innovative therapies such as stem-cell treatment, next-gen dialysis products, and biomarkers for early AKI detection, which can significantly enhance patient outcomes. Companies can leverage collaborative research with academic institutions to fast-track innovation and widen therapeutic portfolios. However, the market faces limitations including high treatment costs, the shortage of skilled nephrologists, and the complex nature of multi-organ failure in critical patients. Moreover, regulatory challenges and the need for extensive clinical validation can delay product launches. Despite these challenges, innovation areas such as AI-driven predictive analytics, personalized medicine approaches, and novel kidney support devices can pave the way for substantial market growth. The AKI treatment market is characterized by a dynamic nature, with a strong emphasis on technological developments and therapeutic advancements. Insights into market dynamics can guide businesses to make informed investment decisions, prioritize R&D efforts, and collaborate strategically. Comprehensive market analysis reveals that addressing unmet medical needs and improving existing treatment efficacy are pivotal pathways toward sustainable business expansion in the AKI treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Kidney Injury Treatment Market

The Acute Kidney Injury Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of kidney failures and kidney-related diseases
  • Growing number of drug approvals for the treatment of kidney disorders
  • Government initiatives to raise awareness about kidney health
• Market Restraints
  • High cost of availing treatment and lack of reimbursements
• Market Opportunities
  • Advancements to enhance kidney treatment options and improve disease detection
  • New hospitals providing kidney treatment and improvements in outpatient care
• Market Challenges
  • Stringent regulations concerning certain kidney injury treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Acute Kidney Injury Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Kidney Injury Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Kidney Injury Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Kidney Injury Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Kidney Injury Treatment Market

A detailed market share analysis in the Acute Kidney Injury Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Kidney Injury Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Kidney Injury Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Kidney Injury Treatment Market

A strategic analysis of the Acute Kidney Injury Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Kidney Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alloksys Life Sciences B.V., Amgen Inc., Angion Biomedica Corp., Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Bayer AG, bioMerieux SA, Dr. Reddys Laboratories Ltd., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Reata Pharmaceuticals Inc. by Biogen Inc., Rockwell Medical, Inc., Silver Creek Pharmaceuticals, Inc., Stealth BioTherapeutics, Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Kidney Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Dialysis and Drug Therapy. The Dialysis is further studied across Continuous Renal Replacement Therapy (CRRT), Intermittent Hemodialysis, and Sustained Low-Efficiency Dialysis (SLED). The Drug Therapy is further studied across Antibiotics, Diuretics, and Immunosuppressive Agents.
• Based on Injury Type, market is studied across Intrinsic-Renal Acute Kidney Injury, Post-Renal Acute Kidney Injury, and Pre-Renal Acute Kidney Injury.
• Based on End-User, market is studied across Ambulatory Surgical Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of kidney failures and kidney-related diseases
    • 5.1.1.2. Growing number of drug approvals for the treatment of kidney disorders
    • 5.1.1.3. Government initiatives to raise awareness about kidney health
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of availing treatment and lack of reimbursements
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements to enhance kidney treatment options and improve disease detection
    • 5.1.3.2. New hospitals providing kidney treatment and improvements in outpatient care
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations concerning certain kidney injury treatment options
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising number of research initiatives to improve dialysis treatment
  • 5.2.2. Injury type: Awareness about underlying causes of kidney injury leading to the creation of treatments for Intrinsic-Renal Acute Kidney Injury
  • 5.2.3. End-user: Improvements in outpatient care leading to rising prevalence of ambulatory surgical centers (ASCs)
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Kidney Injury Treatment Market, by Product

• 6.1. Introduction
• 6.2. Dialysis
  • 6.2.1. Continuous Renal Replacement Therapy (CRRT)
  • 6.2.2. Intermittent Hemodialysis
  • 6.2.3. Sustained Low-Efficiency Dialysis (SLED)
• 6.3. Drug Therapy
  • 6.3.1. Antibiotics
  • 6.3.2. Diuretics
  • 6.3.3. Immunosuppressive Agents

7. Acute Kidney Injury Treatment Market, by Injury Type

• 7.1. Introduction
• 7.2. Intrinsic-Renal Acute Kidney Injury
• 7.3. Post-Renal Acute Kidney Injury
• 7.4. Pre-Renal Acute Kidney Injury

8. Acute Kidney Injury Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals

9. Americas Acute Kidney Injury Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Kidney Injury Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Kidney Injury Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Novartis to Buy Chinook for Up to USD 3.5 Billion, Expanding Kidney Disease Pipeline
  • 12.3.2. CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
  • 12.3.3. SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alloksys Life Sciences B.V.
• 3. Amgen Inc.
• 4. Angion Biomedica Corp.
• 5. Asahi Kasei Medical Co., Ltd.
• 6. B. Braun Melsungen AG
• 7. Baxter International, Inc.
• 8. Bayer AG
• 9. bioMerieux SA
• 10. Dr. Reddys Laboratories Ltd.
• 11. Fresenius Medical Care AG & Co. KGaA
• 12. GlaxoSmithKline PLC
• 13. Johnson & Johnson Services, Inc.
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Otsuka Pharmaceutical Co., Ltd.
• 17. Pfizer Inc.
• 18. Reata Pharmaceuticals Inc. by Biogen Inc.
• 19. Rockwell Medical, Inc.
• 20. Silver Creek Pharmaceuticals, Inc.
• 21. Stealth BioTherapeutics, Inc.
• 22. Teva Pharmaceutical Industries Ltd.